Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; ^$(P < 0.05) significant vs. …”

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”

The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

Subjects:

TH5487 decreases RSV replication in lungs. by Lang Pan (5145221)

CKO mice display decreased skin barrier function and perturbed homeostasis. by Kevin J. Mills (9270966)

Subjects:

Comparison of questionnaire scores among genotypes for the significant associations. by Dai Nogimura (21445649)

Subjects:

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  by Beatrice T. Nganso (4114768)

Subjects:

TH5487 decreases RSV-induced release of lactose dehydrogenase (LDH). by Lang Pan (5145221)

Elevated concentrations of serum MMA among participants with decreased cognitive performance. by Yige Liu (11940344)

Differential Gene Expression Associated with Non-Alcoholic Fatty Liver Disease. by Jiyong Zhang (2498740)

Subjects:

The impact of UV360 on the locomotor activity of zebrafish larvae. by Lihan Xu (18778257)

Subjects:

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Subjects:

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects:

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Subjects:

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Subjects:

IKK KO in microglia leads to increased accumulation of PK-resistant PrP <i>in vitro</i> but decreased accumulation <i>in vivo.</i> by Arielle J. D. Hay (15456341)